Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Capricor Therapeutics (CAPR) Cash & Equivalents (2016 - 2025)

Capricor Therapeutics (CAPR) has 15 years of Cash & Equivalents data on record, last reported at $19.5 million in Q3 2025.

  • For Q3 2025, Cash & Equivalents fell 71.47% year-over-year to $19.5 million; the TTM value through Sep 2025 reached $19.5 million, down 71.47%, while the annual FY2024 figure was $11.3 million, 23.19% down from the prior year.
  • Cash & Equivalents reached $19.5 million in Q3 2025 per CAPR's latest filing, down from $23.2 million in the prior quarter.
  • Across five years, Cash & Equivalents topped out at $68.4 million in Q3 2024 and bottomed at $6.2 million in Q1 2024.
  • Average Cash & Equivalents over 5 years is $24.2 million, with a median of $16.4 million recorded in 2022.
  • Peak YoY movement for Cash & Equivalents: tumbled 81.82% in 2023, then soared 661.05% in 2024.
  • A 5-year view of Cash & Equivalents shows it stood at $34.9 million in 2021, then crashed by 72.47% to $9.6 million in 2022, then skyrocketed by 53.02% to $14.7 million in 2023, then fell by 23.19% to $11.3 million in 2024, then surged by 72.86% to $19.5 million in 2025.
  • Per Business Quant database, its latest 3 readings for Cash & Equivalents were $19.5 million in Q3 2025, $23.2 million in Q2 2025, and $28.8 million in Q1 2025.